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ABSTRACT
Synthetic biology has significantly advanced the
design of mammalian trigger-inducible transgene-
control devices that are able to programme com-
plex cellular behaviour. Fruit-based benzoate deriva-
tives licensed as food additives, such as flavours
(e.g. vanillate) and preservatives (e.g. benzoate), are
a particularly attractive class of trigger compounds
for orthogonal mammalian transgene control devices
because of their innocuousness, physiological com-
patibility and simple oral administration. Capitaliz-
ing on the genetic componentry of the soil bac-
terium Comamonas testosteroni, which has evolved
to catabolize a variety of aromatic compounds, we
have designed different mammalian gene expression
systems that could be induced and repressed by
the food additives benzoate and vanillate. When im-
planting designer cells engineered for gene switch-
driven expression of the human placental secreted
alkaline phosphatase (SEAP) into mice, blood SEAP
levels of treated animals directly correlated with
a benzoate-enriched drinking programme. Addition-
ally, the benzoate-/vanillate-responsive device was
compatible with other transgene control systems and
could be assembled into higher-order control net-
works providing expression dynamics reminiscent of
a lap-timing stopwatch. Designer gene switches us-
ing licensed food additives as trigger compounds to
achieve antagonistic dual-input expression profiles
and provide novel control topologies and regulation
dynamics may advance future gene- and cell-based
therapies.
INTRODUCTION
The rational assembly of mammalian synthetic transcrip-
tion control switches to higher-order control networks that
can programme cellular behaviour in a precise, predictable
and reliable manner (1) has paved the way for the design
of therapeutic devices that have the potential to specifically
kill cancer cells (2,3), modulate the immune system (4,5)
and correct metabolic disorders such as gouty arthritis (6),
obesity (7,8) and diabetes (9,10). For optimal compatibility
with host physiology, the trigger cues that fine-tune thera-
peutic transgene expression in future gene- and cell-based
therapies need to be traceless (9,11,12), physiologically in-
ert (13,14) or biocompatible such as vitamins (15,16), amino
acids (17,18) or licensed food additives (14,19,20). Licensed
food additives are particularly attractive trigger compounds
for modulating heterologous transcription-control devices
as long as they are used at a concentration that is above the
one reached by standard dietary intake to prevent interfer-
ence with meals and below the no observed adverse effect
level (NOAEL) to prevent side effects.
Prokaryotic trigger-adjustable repressors that change
their operator-binding affinity in response to a specific
small-molecule compound have been a continuous source
of molecular parts for the assembly of orthogonal mam-
malian transcription-control devices (1,14,19,21–24). Fol-
lowing a generic design blueprint, the prokaryotic re-
pressors are fused to transactivation/transsilencing do-
mains to produce synthetic transactivators/transsilencers
that activate/repress specific target promoters containing
transactivator/transsilencer-specific operator sites linked
to minimal/constitutive mammalian promoters (1). The
trigger compound typically reduces the affinity of the
transactivator/transsilencer for the cognate promoter and
switches target gene expression OFF/ON in a dose-
dependent manner (1,25). Non-limiting prominent ex-
amples of prokaryotic repressor-derived trigger-inducible
mammalian gene switches are responsive to pristinamycin
(21), erythromycin (22), tryptophan (17) and uric acid (6) as
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well as  -butyrolactone (23), phloretin (19) and vanillic acid
(14); these have been successfully validated in mammalian
cells and mice (see (1) for a comprehensive list). Most of
thesemammalian transgene-control systems are compatible
with each other and can either be used for independent con-
trol of different sets of transgenes or functionally intercon-
nected to provide higher-order control networks (26–29).
Chlorinated benzoic acids are a common class of pollu-
tants introduced into the environment by the use of herbi-
cides (30). The aerobic soil bacterium Comamonas testos-
teroni BR60 contains the plasmid pBRC60, which harbours
the composite transposon Tn5271 encoding the chloroben-
zoate catabolism pathway operon cbaABC (30). Catabolism
of 3-chlorobenzoate (3CBA) is initiated by the binding of
3CBA to the 19.4 kDa MarR-type transcriptional repres-
sor CbaR, which loses its affinity for the two operator sites
(OCbaR) of the PCbaA promoter. This change results in full
expression of the cbaABC operon, thereby producing the
enzymatic components necessary for the sequential break-
down of 3CBA to acetyl-CoA (31).
Previous studies inC. testosteroni have shown that the in-
activation of CbaR and the induction of cbaABC also occur
in the presence of benzoic acid, a plant defence metabolite
that is present at low levels in cranberries, prunes and ap-
ples (32). Benzoate is generally recognized as safe (GRAS)
and is licensed as a food preservative by the US Food
and Drug Administration (FDA) and the European Union
(food additive approval number E210; E211–E213). The no
observed adverse effect level (NOAEL) of dietary sodium
benzoate was estimated to be 1400 mg/kg (33). Following
food intake, benzoate rapidly reaches the bloodstream and
is eliminated by renal clearance within 24 h (34). With its
GRAS status (35), highNOAEL level (36), approval as food
additive (37), optimal bioavailability (38) and clearance rate
(34) as well as its metabolic inertness (35), benzoate can be
considered an almost ideal orthogonal trigger compound
to control transgene expression in mammalian cells and or-
ganisms.
Capitalizing on C. testosteroni’s aromatic acid-
catabolizing components, we have engineered a synthetic
mammalian gene switch that is responsive to antagonistic
input by the two food additives benzoate and vanillate and
fine-tunes transgene expression in different mammalian cell
lines as well as in mice. Synthetic gene switches with antag-
onistic dual-input control capacity add a new instrument
to the synthetic biology toolbox and expand the genetic
intervention portfolio that may foster novel advances in
gene- and cell-based therapies.
MATERIALS AND METHODS
Plasmid design
Comprehensive design and construction details for all ex-
pression vectors are provided in Table 1. The assembly of
some plasmids required annealing complementary oligonu-
cleotides. For optimal annealing, 50 pmol of each oligonu-
cleotide was mixed in 50 l ddH2O-diluted 1x NEB Buffer
4 (New England Biolabs, Ipswich, MA, USA), heated for
10 min at 95◦C, cooled down over 4 h to 22◦C and incu-
bated at 22◦C for another 2 h prior to cloning into the corre-
sponding vector backbone. All relevant genetic components
have been confirmed by sequencing (Microsynth, Balgach,
Switzerland).
Cell culture and transfection
Human embryonic kidney cells (HEK-293T, ATCC: CRL-
11268), human cervical adenocarcinoma cells (HeLa,
ATCC: CCL-2) and telomerase-immortalized human mes-
enchymal stem cells (hMSCs (39)) were cultivated in 10-
cm tissue culture dishes containing 10 ml Dulbecco’s mod-
ified Eagle’s medium (DMEM; Invitrogen, Basel, Switzer-
land) supplemented with 10% foetal bovine serum (Sigma-
Aldrich, Buchs, Switzerland, cat. no. F7524, lot no.
022M3395) and 1% (v/v) penicillin/streptomycin solution
(Biowest, Nuaille´, France, cat. no. L0022–100) at 37◦C in
a humidified atmosphere containing 5% CO2. For main-
tenance (10-cm tissue culture dish), passaging (10-cm tis-
sue culture dish) and transfection (6- and 48-well plates),
cells of pre-confluent cultures were detached by incubation
in 3 ml Trypsin-EDTA (Biowest, Nuaille´, France, cat. no.
L0940) for 3 min at 37◦C, collected in 10 ml cell culture
medium, centrifuged for 3 min at 290 × g and resuspended
inDulbecco’smodifiedEagle’smediumat standard cell den-
sities (15 000 cells in 100 l per well of a 96-well plate;
25 000 cells in 300 l per well of a 48-well plate; 50 000
cells in 500 l per well of a 24-well plate; 200 000 cells in
2 ml per well of a 6-well and 1 × 106 cells in 10 ml per
10 cm tissue culture dish). Cell concentrations and viabil-
ity were profiled with a CASYR© Cell Counter and Analyser
SystemModel TT (Roche Diagnostics GmbH, Mannheim,
Germany). For transfection, cells cultivated in 6-well cul-
ture dishes were incubated for 6 h with 400 l (for 48-well
plates: 50 l) of a 1:3 (1:5, HeLa cells only) PEI:DNA mix-
ture (w/w) (polyethyleneimine; MW 40 000, stock solution
1mg/ml in ddH2O; Polysciences, Eppelheim,Germany; cat.
no. 24765–2) containing 2.0 g (for 48-well plates: 0.5 g)
of total DNA (preparation: 15 min at 22◦C). After transfec-
tion, the culture medium was replaced by PEI-free medium
(2 ml for 6-well and 300 l for 48-well plates), and the engi-
neered cells were used for a dedicated experiment.
Quantification of reporter gene expression
The production of human placental secreted alkaline
phosphatase (SEAP) was quantified in culture super-
natants according to a p-nitrophenylphosphate-based light
absorbance time course (40). The SEAP levels of the
serum were profiled using a chemiluminescence-based as-
say (Roche Diagnostics GmbH, Mannheim, Germany; cat.
no. 11 779 842 001). Gaussia luciferase was quantified using
the BioLux R© Gaussia luciferase assay kit (New England Bi-
olabs, MA, USA; cat. no. E3300S) and the EnVision 2104
multilabel plate reader (Envision 2104 Plate-reader, Perkin
Elmer, MA, USA) by integrating the luminescence signal
for 2 s per well (40).
qRT-PCR
Total RNA was isolated from transfected HeLa using the
ZR RNAMiniPrepTM kit (Zymo Research, CA, USA; cat.
no. R1064), treated with DNaseI (Thermo Scientific, cat.
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Table 1. Plasmids designed and used in this study
Plasmid Description
Reference
pSEAP2-Control Constitutive mammalian SEAP expression vector (PSV40-SEAP-pA). Clontech, CA
pUC57 pUC19-derived prokaryotic expression vector. GeneScript, NJ
pCK25 Constitutive mUTS expression vector (PhEF1-mUTS-pA). (6)
pCK189 Constitutive VanA4 expression vector (PSV40-VanA4-pA). (14)
pCK191 Vanillic acid-inducible SEAP expression vector (PVanON8-SEAP-pA). (14)
pDA43 Tetracycline-repressible GLuc expression vector (PhCMV*-1-GLuc-pA). (25)
pKR38 Constitutive mammalian KstR-VP16 expression vector (PSV40-KstR-VP16-pA). Unpublished
pKR80 Constitutive mammalian KstR-KRAB expression vector (PhEF1-KstR-KRAB-pA). Unpublished
pMF111 Tetracycline-repressible SEAP expression vector (PhCMV*-1-SEAP-pA). (44)
pMG10 Phloretin-repressible SEAP expression vector (PTtgR1-SEAP-pA). (19)
pMG11 Constitutive TtgA1 expression vector (PSV40-TtgA1-pA). (19)
pSAM200 Constitutive tTA expression vector (PSV40-tTA-pA). (44)
pWW124  -butyrolactone (SCB1)-repressible SEAP expression vector (PSPA-SEAP-pA). (23)
pMX34 Constitutive CTS1 expression vector (PhEF1-CTS1-pA; CTS1, KRAB-CbaR). This work
CbaR was PCR-amplified from pMX43 using oligonucleotides OMX49
(5′-gaatgatctctgggcgcgcATGCTGGCCCGTGACCCCCGGAAAAG-3′) and OMX48
(5′-ggccctctagattaCTCCTGAGGGCTCTCCCGATGCCAATG-3′), restricted with
BssHII/XbaI and cloned into the corresponding sites (BssHII/XbaI) of pCK25.
pMX38 Benzoic and vanillic acid-responsive SEAP expression vector (PCTA-O2-SEAP-pA; PCTA-O2,
(OCbaR)2-PhCMVmin). OCbaR was PCR-amplified from pWW124 using oligonucleotides
OMX33 (5′-ccacctgacgtcgacacaagttgctaaaccaacaacatgtttgacacaagttgctaaaccaacaacatccgcaaat
TCGAGCTCGGTACCCGGGTCGAGT-3’) and OMX24 (5′-CTTGAGCACATAGCCTG
GACCGTTTCCGTA-3′), restricted with AatII/EcoRI and cloned into the corresponding
sites (AatII/EcoRI) of pWW124.
This work
pMX39 Benzoic and vanillic acid-responsive SEAP expression vector (PCTS1-SEAP-pA;
PCTS1, PSV40-OCbaR). OCbaRwas introduced by PCR-amplification of pSEAP2-Control with
oligonucleotides OMX36 (5′-tagtaataagcttgaaagttgctaaaccaacaacatccgCCACCATGCTGCT
GCTGCTGCTGCTGCTGGG-3′) and OMX24 (5′-CTTGAGCACATAGCCTGGACCGT
TTCCGTA-3′), restricted with HindIII/PstI and cloned into the corresponding sites (HindIII/
PstI) of pSEAP2-Control.
This work
pMX40 Benzoic and vanillic acid-responsive SEAP expression vector (PCTS2-SEAP-pA; PCTS2,
PSV40-(OCbaR)2). (OCbaR)2 was introduced by PCR-amplification of pSEAP2-Control with
oligonucleotides OMX35 (5′-tagtaatAagcttgaaagttgctaaaccaacaacatgtttgaca
caagttgctaaaccaacaacatccgCCACCATGCTGCTGCTGCTGCTGCTGCTGGG-3’) and O
MX24 (5′-CTTGAGCACATAGCCTGGACCGTTTCCGTA-3′), restricted with HindIII/Ps
tI and cloned into the corresponding sites (HindIII/PstI) of pSEAP2-Control.
This work
pMX41 Benzoic and vanillic acid-responsive SEAP expression vector (PCTS3-SEAP-pA; PCTS3,
PSV40-(OCbaR)3). (OCbaR)3 was introduced by PCR-amplification of pSEAP2-Control with
oligonucleotides OMX43 (5′-caaaaagcttgaaagttgctaaaccaacaacatgtttgaca
caagttgctaaaccaacaacatgtttgacacaagttgctaaaccaacaacatccgCCACCATGCTGCTGCTGCT
GC-3′) and OMX24 (5′-CTTGAGCACATAGCCTGGACCGTTTCCGTA-3’), restricted w
ith HindIII/PstI and cloned into the corresponding sites (HindIII/PstI) of pSEAP2-Control.
This work
pMX42 Benzoic and vanillic acid-responsive SEAP expression vector (PCTS-O3P2-SEAP-pA; PCTS-O3P2,
(OCbaR)3-PSV40-(OCbaR)2). Oligonucleotides OMX44 (5′-CTTGAAAGTTGCTAAACCAAC
AACATGTTTGACACAAGTTGCTAAACCAACAACATGTTTGACACAAGTTGCTAAAC
CAACAACACTATCGATAGGTACCGAGCTCTTA-3′) and OMX45 (5′-cgcgTAAG
AGCTCGGTACCTATCGATAGTGTTGTTGGTTTAGCAACTTGTGTCAAACATGTT
GTTGGTTTAGCAACTTGTGTCAAACATGTTGTTGGTTTAGCAACTTTCAAGgta
c-3′) were annealed and cloned into the KpnI/MluI-restricted pMX39.
This work
pMX43 Constitutive CTA expression vector (PSV40-CTA-pA; CTA, CbaR-VP16). This work
Custom-designed mammalian codon-optimized cbaR was excised from pUC57 with
NotI/BssHII and cloned into the corresponding sites (NotI/BssHII) of pKR38.
pMX45 Constitutive CTS2 expression vector (PhEF1-CTS2-pA; CTS2, CbaR-KRAB). This work
Custom-designed mammalian codon-optimized cbaR was excised from pUC57 with
NotI/BssHII and cloned into the corresponding sites (NotI/BssHII) of pKR80.
pMX78 Vanillic acid-inducible GLuc expression vector (PVanON8-GLuc-pA). GLuc was excised from
pDA43 using EcoRI/FseI and cloned into the corresponding sites (EcoRI/FseI) of pCK191.
This work
Oligonucleotides:Restriction endonuclease-specific sites are underlined, annealing base pairs are indicated in capital letters and the operator module OCbaR
is shown in bold.
Abbreviations:CbaR,Comamonas testosteroniBR60 repressor of the 3-chlorobenzoate catabolism;CTA, CbaR-derived benzoic and vanillic acid-dependent
transactivator (CbaR-VP16); CTS1, CbaR-derived benzoic and vanillic acid-dependent transsilencer variant 1 (KRAB-CbaR); CTS2, CbaR-derived
benzoic and vanillic acid-dependent transsilencer variant 2 (CbaR-KRAB); GLuc, Gaussia princeps luciferase; HucR,Deinococcus radiodurans uric acid-
dependent repressor; KRAB, Krueppel-associated box protein of the human kox-1 gene; KstR, Mycobacterium tuberculosis repressor of the cholesterol
catabolism; mUTS, mammalian urate-dependent transsilencer (KRAB-HucR); OCbaR, CbaR-specific operator; OPapRI, ScbR-specific operator; OTtgR,
TtgA1-specific operator; pA, polyadenylation site; PCTA-O2, CTA-specific benzoic and vanillic acid-responsive promoter ((OCbaR)2-PhCMVmin); PCTS1,
benzoic and vanillic acid-responsive promoter (PSV40-OCbaR); PCTS2, benzoic and vanillic acid-responsive promoter (PSV40-(OCbaR)2); PCTS3, benzoic
and vanillic acid-responsive promoter (PSV40-(OCbaR)3); PCTS-O3P2, benzoic and vanillic acid-responsive promoter ((OCbaR)3-PSV40-(OCbaR)2); PhEF1 ,
human elongation factor 1 promoter; PhCMV, human cytomegalovirus immediate early promoter; PhCMVmin, minimal version of PhCMV; PhCMV*-1,
tetracycline-responsive promoter (tetO7-PhCMVmin); PSPA,  -butyrolactone (SCB1)-repressible promoter (OPapRI-PhCMVmin); PSV40, simian virus 40 pro-
moter; PTtgR1, phloretin-responsive promoter (OTtgR-PhCMVmin); PVanON8 vanillic acid-inducible promoter (PhCMV-VanO8); SEAP, human placental se-
creted alkaline phosphatase; SCB1, 2-(1′-hydroxy-6-methylheptyl)-3-(hydroxymethyl)-butanolide; ScbR, Streptomyces coelicolor  -butyrolactone (SCB1)-
specific quorum-sensing receptor; tetO, TetR-specific operator; TetR, Escherichia coli Tn10-derived tetracycline-dependent repressor of the tetracycline
resistance gene; tTA, tetracycline-dependent transactivator (TetR-VP16); TtgA1, phloretin-dependent transactivator (TtgR-VP16); VanA4, VanR-derived
vanillic acid-dependent transsilencer (VanR-KRAB);VanO, VanR-specific operator.VanR, vanillic acid-dependent repressor of theCaulobacter crescentus
VanAB gene cluster; VP16, Herpes simplex virus-derived transactivation domain.
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no. EN0521) and cDNA was synthesized using the Ap-
plied Biosystems High Capacity cDNA Reverse Transcrip-
tion Kit (Life Technologies, CA, USA; cat. no. 4368814).
qRT-PCR-based quantification of SEAP transcripts was
performed with the Eppendorf Realplex2 Mastercycler
(Eppendorf GmbH, Hamburg, Germany), using Invitro-
gen SYBRR© Green PCR Master Mix (Life Technologies,
CA, USA; cat. no. 4309155) and the custom-designed
primers (forward: 5′-GTCAGTGGGAGTGGTAACCA-
3′, reverse: 5′-ACATGTACTTTCGGCCTCCA-3′) pur-
chased from Sigma-Aldrich (Buchs, Switzerland). The fol-
lowing amplification parameters were used: 2 min at 50◦C,
20 s at 95◦Cand 60 cycles of 1 s at 95◦C, followed by 1min at
60◦C. The relative cycle threshold (CT) was determined and
normalized against the endogenous human glyceraldehyde
3-phosphate dehydrogenase (GAPDH) gene.
Chemicals
Ethanol (EtOH; cat. no. 02860), dimethyl sulfoxide
(DMSO; cat. no. D8418), benzoic acid (stock solution 1
M in EtOH; cat. no. 242381), sodium benzoate (stock
solution 1.7 M in ddH2O; cat. no. B3420), vanillic acid
(stock solution 200 mM in EtOH, cat. no. 94770), 3,4-
dihydroxybenzoic acid (stock solution 200 mM in EtOH,
cat. no. 37580), 3-hydroxybenzoic acid (stock solution
100 mM in EtOH, cat. no. H20008), 4-hydroxybenzoic
acid (stock solution 100 mM in EtOH, cat. no. 240141),
homo-vanillyl-alcohol (stock solution 50 mM in EtOH,
cat. no. 148830), homo-vanillic-acid (stock solution 20
mM in EtOH, cat. no. H1252), tetracycline (stock so-
lution 2mM in ddH2O, cat. no. T7660) and phloretin
(stock solution 25mM in DMSO, cat. no. P7912) were pur-
chased fromSigma-Aldrich (Buchs, Switzerland). Ethyl 3,4-
dihydroxybenzoate (stock solution 200 mM in EtOH, cat.
no. D0571) was purchased from Tokyo Chemical Industry
(Tokyo, Japan).
Soft drinks
Ocean Spray R© (0.01% benzoic acid, (41)), Guarana
Antarctica R© (<0.1% sodium benzoate, (37)) and Vanilla
Coke R© were purchased at local supermarkets, degassed by
extensive shaking and directly administered to mice (4 ×
200 l). A vanillin syrup was produced by dissolving 13 g
of vanillin sugar (Dr Oetker; Bielefeld, Germany) in 50 ml
ddH2O.
Animal experiments
Intraperitoneal implants were produced by encapsulat-
ing transgenic HeLa cells into coherent alginate-poly-(L-
lysine)-alginate beads (400 m; 200 cells/capsule) using
an Inotech Encapsulator Research Unit IE-50R (Encap-
BioSystems Inc.) set to the following parameters: 200 m
nozzle with a vibration frequency of 1025 Hz, 25-ml syringe
operated at a flow rate of 410 units and 1.12 kV voltage
for bead dispersion (8). Eight-week-old female OF1 mice
(oncins France souche 1, Charles River Laboratory, Lyon,
France) were intraperitoneally injected with 1 ml of phos-
phate buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl,
4.3 mM Na2HPO4, 1.4 mM KH2PO; pH 7.4) containing 2
× 106 encapsulated pMX34/pMX42-transgenic HeLa cells.
One hour after implantation, the treated animals received
200 l of the trigger compound-containing solutions while
control groups received 200 l of PBS or ddH2O. Blood
samples were collected 24 h after treatment, and blood
serum was isolated using microtainer SST tubes accord-
ing to the manufacturer’s instructions (centrifugation for 5
min at 10 000 x g; Becton Dickinson, Plymouth, UK; cat.
no. 365967). All experiments involving animals were per-
formed according to the directive of the European Com-
munity Council (2010/63/EU), approved by the FrenchRe-
public (No. 69266310; project No. DR2013–01 (v2)) and
carried out by Ghislaine Charpin-El Hamri at the Institut
Universitaire de Technologie, IUT, F-69622 Villeurbanne
Cedex, France.
RESULTS
Design and validation of the Comamonas testosteroni CbaR-
derived synthetic mammalian transactivator (CTA)
By fusing the Herpes simplex virus-derived transacti-
vation domain (VP16) to the C′-terminus of the Co-
mamonas testosteroni repressor CbaR, we created the
synthetic mammalian transcription factor CTA (CbaR-
derived transactivator; pMX43, PSV40-CTA-pA; CTA,
CbaR-VP16), whose expression did neither reduce the via-
bility nor the metabolic capacity of mammalian cells (Sup-
plementary Figure S1A). This transcription factor was
able to bind to a chimeric promoter (PCTA-O2, (OCbaR)2-
PhCMVmin) consisting of a CTA-specific CbaR-derived tan-
dem operator module (OCbaR)2 5′ of a minimal version
of the human cytomegalovirus immediate-early promoter
(PhCMVmin) and activate expression of the reporter pro-
tein SEAP (human placental secreted alkaline phosphatase;
pMX38, PCTA-O2-SEAP-pA) (Figure 1A). When cotrans-
fecting pMX43 (PSV40-CTA-pA) and pMX38 (PCTA-O2-
SEAP-pA) at different ratios into human embryonic kid-
ney cells (HEK-293), the engineered cells produced and se-
creted SEAP at levels that depended on the relative abun-
dance of the transfected CTA- and SEAP-encoding vec-
tors (Figure 1B). Control experiments with isogenic popu-
lations lacking pMX43 (PSV40-CTA-pA) only showed basal
SEAP levels, indicating that the binding of CTA to PCTA-O2
was indeed essential for transgene expression inmammalian
cells (Figure 1B). Previous studies in C. testosteroni have
shown that the binding of CbaR to OCbaR-containing pro-
moters was derepressed by 3-chlorobenzoate as well as
3,4-dihydroxy-benzoate to initiate the catabolism of the
compounds (30). However, CbaR’s natural trigger com-
pounds 3-chlorobenzoate and 3,4-dihydroxy-benzoate were
too toxic for use in mammalian cells, and the chocolate
catabolite 3-hydroxy-benzoate (42) was not able to modu-
late SEAP expression in mammalian cells at concentrations
that are licensed for use as a food additive (Figure 1C and
D).
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Figure 1. Comamonas testosteroni CbaR-derived transactivation-based mammalian gene switch. (A) Design and functionality of the CbaR-derived
transactivation-based transgene control system. C′-terminal fusion of CbaR to the transactivation domain VP16 of the Herpes simplex virus results
in a CbaR-derived transactivator CTA (pMX43, PSV40-CTA-pA; CTA, CbaR-VP16). Following constitutive expression by the Simian virus 40 pro-
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The food additives benzoic acid and vanillic acid modulate
CTA-PCTA-O2-driven transgene expression
To identify non-toxic, bioavailable and cell-permeable trig-
ger compounds modulating CTA’s capacity to bind and ac-
tivate PCTA-O2-driven transgene expression in mammalian
cells, we operated the CTA-PCTA-O2 system as a mam-
malian cell-based screening platform (20,43). Therefore,
pMX43/pMX38-transfected HEK-293 cultures were ex-
posed to various aromatic acids at concentrations that are
naturally present in edible plants and fruits (38). Then,
SEAP levels were profiled in the culture supernatants
to reveal the compounds’ control capacity (Figure 1C).
Benzoic acid, 3,4-dihydroxybenzoic acid and ethyl 3,4-
dihydroxybenzoate reduced SEAP levels of CTA-PCTA-O2-
transgenic cultures, making them prime candidates to trig-
ger the release of CTA from PCTA-O2 (Figure 1C). However,
in parallel control assays using isogenic cultures transfected
with the constitutive SEAP expression vector (pSEAP2-
Control, PSV40-SEAP-pA), 3,4-dihydroxybenzoic acid and
ethyl 3,4-dihydroxybenzoate actually reduced constitutive
SEAP production due to their cytotoxicity (Figure 1D).
Thus, the licensed food preservative benzoic acid was iden-
tified as a non-toxic control compound that abolishes the
CTA-PCTA-O2 interaction and shuts down CTA-mediated
PCTA-O2-driven transgene expression in mammalian cells.
Interestingly, the cell-based screening assay also revealed
another licensed food additive, vanillic acid, as control com-
pound. In contrast to benzoic acid, which triggers the re-
lease of CTA from PCTA-O2 and therefore represses trans-
gene expression, vanillic acid seems to increase the affin-
ity of CTA to PCTA-O2, thereby boosting the system’s ex-
pression performance (Figure 1C). Therefore, CTA is a syn-
thetic transcription factor that accepts both boosting (vanil-
lic acid) and inactivating (benzoic acid) control inputs. This
unique antagonistic dual-input control characteristic rem-
iniscent of an electrical stepping switch (Figure 1E) was
successfully validated in other human cell lines (Figure 1F)
as well as in mice (Supplementary Figure S2), where both
trigger compounds independently fine-tunedCTA-PCTA-O2-
mediated SEAP expression in a dose-dependent manner
(Figure 1G). qRT-PCR-based analysis of SEAP mRNA
levels confirmed the dual-input control characteristics of
the CbaR-derived gene switch (Figure 1H). Comparative
analysis of the CbaR-derived gene switch with other estab-
lished transcription-control devices such as the tetracycline-
(TET; (44)) and phloretin- (PEACE; (19)) responsive ex-
pression systems revealed similar basic control performance
while the expression mediated by the CbaR-derived gene
switch could be boosted by vanillic acid to about three times
the maximum levels of the TET and PEACE counterparts
(Figure 1I).
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
moter (PSV40), CTA binds and activates a chimeric promoter PCTA-O2 (pMX38, PCTA-O2-SEAP-pA; PCTA-O2, (OCbaR)2-PhCMVmin) containing a tandem
CbaR/CTA-specific operator module (OCbaR)2 5′ of a minimal human cytomegalovirus immediate early promoter (PhCMVmin), which is set to drive expres-
sion of human placental secreted alkaline phosphatase (SEAP). In the presence of trigger compounds, CTA is released from PCTA-O2, and SEAP expression
is shut down. (B) Validation of CTA-mediated PCTA-O2-driven SEAP expression in HEK-293 cells. HEK-293 cells were cotransfected with different ratios
(w/w; 0.6 g total DNA) of transactivator-encoding pMX43 and the SEAP reporter plasmid pMX38, and SEAP expression was scored in the culture
supernatant after 48 h. The data are show as the mean ± SD, n = 3. (C) Impact of small-molecule compounds on CTA/PCTA-O2-controlled transgene
expression. HEK-293 cells cotransfected with pMX43 and pMX38 at a 1:3 ratio (w/w; 2 g total DNA) were reseeded at a standard cell density in a
96-well plate (15 000 cells in 100 l per well) containing potential trigger compounds at the indicated concentrations (BA: benzoic acid; VA: vanillic acid;
3,4-DHB: 3,4-dihydroxybenzoic acid; Et-3,4D: ethyl 3,4-dihydroxybenzoate; 3-HBA: 3-hydroxy-benzoate; 4-HBA: 4-hydroxy-benzoate; HVOH: homo-
vanillyl-alcohol; HVA: homo-vanillic-acid). pMX38-transfected cells were used as a basal expression control. The SEAP levels were profiled in the culture
supernatant after 48 h. The data are shown as the mean ± SD, n = 3. (D) Cytotoxicity score of the control compounds shown in Figure 1C. Cytotoxicity
was assessed by scoring the impact of control molecules on viability and metabolic integrity by profiling SEAP expression of HEK-293 cells transfected
with the constitutive SEAP expression vector pSEAP2-control. pSEAP2-control-transfected HEK-293 cells cultivated in the absence of any compound
and HEK-293 cells cultivated in the presence of 1% EtOH, which represents the final solvent concentration present in compound-containing cultures, were
used as controls. The SEAP levels were profiled in the culture supernatant 48 h after transfection and compound addition. The data are shown as the
mean ± SD, n = 3. (E) Schematic of the step switch-like control characteristic produced by the dual-input CbaR-derived gene switch. CTA transactivates
PCTA-O2 while accepting both boosting (vanillic acid, VABOOST) and inactivating (benzoic acid, BAOFF) control inputs. These three distinct output levels
(OFF, ON, BOOST) are reminiscent of an electrical stepping switch (0, I, II). (F) Dual-input control characteristic of the CTA/PCTA-O2 expression device.
HEK-293, HeLa and hMSC cells were cotransfected with pMX43 and pMX38 at a 1:3 ratio (w/w; 0.5 g total DNA). The SEAP levels were profiled
in the culture supernatant 48 h after cultivation in medium containing either benzoic acid (BA, 750 M) or vanillic acid (VA, 750 M). Compound-free
and pMX38-transfected cultures were used as controls. The data are shown as the mean ± SD, n = 3. (G) Dose-dependent dual-input control of the
CTA/PCTA-O2 gene switch. HeLa cells were cotransfected with pMX43 and pMX38 at a 1:3 (w/w; 0.5 g total DNA) ratio, and SEAP levels were profiled
in the culture supernatant 48 h after cultivation of the cells in medium containing different concentrations (0–1000 M) of either benzoic or vanillic acid.
pMX38-transfected cells were used as a basal expression control. The data are shown as the mean ± SD, n = 3. (H) qRT-PCR analysis of SEAP mRNA
levels. HeLa cells were cotransfected with pMX43 and pMX38 at a 1:3 ratio (w/w; 2 g total DNA) and cultivated for 48 h in medium containing either
benzoic acid (BA, 750 M), vanillic acid (VA, 750 M) or no control compound (CTA). The SEAP transcript levels were profiled relative to the basal
expression control (cells transfected only with pMX38). The analysis was performed in triplicate. (I) Comparative analysis of different mammalian small
molecule-repressible transcription-control systems. HeLa cells were cotransfected with the TET- (pSAM200/pMF111), PEACE- (pMG11/pMG10) and
CbaR-derived (pMX43/pMX38) control components at a 1:1 ratio (w/w; 0.5 g total DNA) and cultivated for 48 h in the presence (+, repression) or
absence (−, induction) of the corresponding regulating (2M tetracycline, 40 Mphloretin and 750Mbenzoic acid) and boosting (750 Mvanillic acid)
compounds before SEAP was quantified in the culture supernatant. Cells transfected exclusively with the reporter constructs (TET, pMF111; PEACE,
pMG10; CbaR-derived gene switch, pMX38) were used as negative controls. The data are shown as the mean ± SD, n = 3. Fold-changes in SEAP expres-
sion were calculated by dividing absolute SEAP levels (induction, repression, boosted induction) by the basal SEAP levels produced by the reporter plasmid
used as isogenic negative control. (J) Dose-dependent benzoic acid-mediated repression of vanillic acid boosted SEAP expression by the CTA/PCTA-O2
device. HeLa cells were cotransfected with pMX43 and pMX38 at a 1:3 ratio (w/w; 2 g total DNA), collected in culture medium containing different
concentrations of vanillic acid (20, 100 or 500 M) and reseeded at standard concentration into the wells of a 96-well plate (15 000 cells in 100 l per well)
containing the indicated concentrations of benzoic acid. Forty-eight hours after the addition of benzoic acid, the SEAP levels were profiled in the culture
supernatant. The data are shown as the mean ± SD, n = 3.
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Simultaneous control of CTA by benzoic acid and vanillic
acid
Although we have observed that the CTA-PCTA-O2 device
accepted opposing dose-dependent input by vanillate (ex-
pression boosting) and benzoate (expression inactivation),
it remains to be shown what impact the presence of both
control compounds has on the overall transgene expression
output. We have therefore programmed SEAP expression
of pMX43/pMX38-transgenic HeLa cells to defined lev-
els by exposing the cultures to specific vanillate concentra-
tions (20, 100 and 500 M) and then scored benzoic-acid
dose-dependent shut down of SEAP expression (Figure 1J).
Interestingly, both compounds had independent control of
CTA, and neither of them seemed to dominate CTA ac-
tivity. Consequently, increased vanillate-boosted SEAP ex-
pression levels required higher benzoate concentrations to
reverse the SEAP expression state. Thus, the overall SEAP
expression level mediated by the CTA-PCTA-O2 device di-
rectly correlates with the relative concentrations of the two
control compounds (Figure 1J).
Design and validation of synthetic mammalian transsilencers
(CTS) with benzoate-inducing and vanillate-repressing dual-
input responsiveness
To engineer a benzoic acid-inducible and vanillic acid-
repressible dual-input control device, we designed synthetic
transsilencers (CTS) by fusing the Krueppel-associated
box (KRAB) domain of the human kox-1 gene either to
the N′-(pMX34, PhEF1-CTS1-pA; CTS1, KRAB-CbaR) or
the C′-terminus (pMX45, PhEF1-CTS2-pA; CTS2, CbaR-
KRAB) of CbaR. CTS1/2 bind and silence chimeric
promoters (PCTS) consisting of a constitutive promoter
(PSV40) containing one (pMX39, PCTS1-SEAP-pA; PCTS1,
PSV40-OCbaR), two (pMX40, PCTS2-SEAP-pA; PCTS2, PSV40-
(OCbaR)2) or three (pMX41, PCTS3-SEAP-pA; PCTS3, PSV40-
(OCbaR)3) 3′ OCbaR operator modules or multiple flanking
OCbaR’s (pMX42; PCTS-O3P2-SEAP-pA; PCTS-O3P2, (OCbaR)3-
PSV40-(OCbaR)2) (Figure 2A). A direct comparison of both
CTS configurations revealed that the N′-terminal fu-
sion of KRAB to CbaR (CTS1, KRAB-CbaR) resulted
in tighter repression of the target promoter (Figure 2B
and C). Constitutive expression of CTS1 did neither re-
duce the viability nor the metabolic capacity of mam-
malian cells (Supplementary Figure S1B). Furthermore, the
PCTS-O3P2 promoter showed the lowest basal SEAP expres-
sion level and the highest SEAP induction profile. There-
fore, the CTS1/PCTS-O3P2 device was chosen for all further
experiments (Figure 2C). Exposure of pMX34/pMX42-
transgenic HeLa cells to increasing concentrations of ben-
zoic acid triggers the release of CTS1 from PCTS-O3P2, re-
sulting in reversible (Figure 2D) and dose-dependent dere-
pression of SEAP expression (Figure 2E). In contrast, vanil-
late increased the affinity of CTS1 for PCTS-O3P2, thereby de-
creasing benzoate-inducible transgene expression and im-
proving overall tightness and the dynamic range of the gene
switch (Figure 2E). Therefore, CTS1 retained the dual-input
characteristics of CTA because transgene expression in-
duced to high levels by benzoate could be programmed to
specific intermediate levels by the addition of the repressing
input vanillate (Figure 2F). Furthermore, a kinetic analy-
sis of benzoate-induced pMX34/pMX42-transgenic HeLa
cells revealed that SEAP expression could be stopped at any
point in time by the addition of different vanillic acid con-
centrations (Figure 2G and H).
A synthetic gene network with a vanillate control interface
To demonstrate the compatibility of theCTS1/PCTS-O3P2 de-
vice with other transgene control modalities and to assess
its potential for the assembly of higher-order control cir-
cuits, we combined the dual-input benzoate-inducible and
vanillic acid-repressible designer switch set to control SEAP
expression with the previously established VACON system
(pCK189, PSV40-VanA4-pA; pMX78, PVanON8-GLuc-pA)
(14). The VACON system allows exclusive vanillic acid-
inducible Gaussia princeps luciferase (GLuc) expression
in mammalian cells (Figure 3A). When combining the
CTS1/PCTS-O3P2 device (pMX34/pMX42) with the VACON
(pCK189/pMX78) system in the same cell, vanillic acid
provides a functional control link between the two sys-
tems and enables mutually exclusive expression switches
of the two reporter proteins, SEAP (controlled by the
CTS1/PCTS-O3P2 device) and GLuc (controlled by VACON).
In particular, the combined transgene control network en-
ables dose-dependent benzoate-inducible SEAP expression
that could be stopped at any point in time by the addi-
tion of vanillic acid, which concomitantly triggers VACON-
mediated GLuc expression. Thus, a single trigger com-
pound such as vanillic acid is able to simultaneously stop
(CTS1/PCTS-O3P2-driven SEAP expression) and turn on
(VACON-driven GLuc expression) the expression of differ-
ent sets of transgenes (Figure 3B). These control dynamics
are reminiscent of a lap-timing stop watch in which ben-
zoic acid represents the ‘start button’ and vanillic acid de-
fines the ‘lap button’ that holds the time value of the first
lap (SEAP expression) while initiating the recording of the
second lap (GLuc expression) (Figure 3C).
Validation of benzoate-inducible transgene expression inmice
To assess the benzoate-inducible CTS1/PCTS-O3P2 device
in vivo, we microencapsulated pMX34/pMX42-transgenic
HeLa cells into coherent, semi-permeable and immunopro-
tective alginate-poly-(L-lysine)-alginate beads (Figure 4A)
and implanted them into the peritoneum of mice where
they become vascularized and connected to the blood-
stream (7). The mice were offered to drink water contain-
ing different concentrations of benzoate (0–1000 mg/kg)
and correlating SEAP levels in the bloodstream showed
benzoate dose-dependent transgene activation and con-
firmed the precise expression adjustment by this food
additive in mice (Figure 4Bi). Likewise, treated animals
that drank CTS1/PCTS-O3P2-activating benzoate concentra-
tions but received different vanillate concentrations (0–500
mg/kg) showed dose-dependent inhibition of SEAP expres-
sion (Figure 4Bii), which confirms the unique dual-input
characteristic of CTS1 in vivo.When feedingmice with com-
mercial soft drinks such as Ocean Spray (cranberry juice) or
Guarana Antarctica (guarana lemonade), which are known
for their high natural and spiked benzoate concentrations,
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Figure 2. Comamonas testosteroniCbaR-derived transsilencing-based gene switch. (A) Design and functionality of the CbaR-derived transsilencing-based
transgene control system. N-terminal (pMX34, PhEF1-CTS1-pA; CTS1, KRAB-CbaR) or C′-terminal (pMX45, PhEF1-CTS2-pA; CTS2, CbaR-KRAB)
fusion of CbaR to the transsilencing Krueppel-associated box (KRAB) domain of the human kox-1 gene resulted in the CbaR-derived transsilencers
CTS1/2. Following constitutive expression by the human elongation factor 1 alpha promoter (PhEF1), CTS1/2 bind and silence chimeric promoters con-
sisting of the constitutive Simian virus 40 promoter (PSV40) linked to one (pMX39, PCTS1-SEAP-pA; PCTS1, PSV40-OCbaR), two (pMX40, PCTS2-SEAP-pA;
PCTS2, PSV40-(OCbaR)2) and three (pMX41, PCTS3-SEAP-pA; PCTS3, PSV40-(OCbaR)3) 3′ CbaR/CTS1/2-specific operator modules (OCbaR) or flanked by
multiple OCbaR’s (pMX42; PCTS-O3P2-SEAP-pA; PCTS-O3P2, (OCbaR)3-PSV40-(OCbaR)2). All promoters were set to drive the expression of human placental
secreted alkaline phosphatase (SEAP). The presence of benzoic acid triggers the release of CTS1/2 from their cognate PCTS promoters, resulting in the
activation of SEAP expression. The presence of vanillic acid increases the affinity of CTS1/2 for PCTS and thus inhibits benzoate-inducible transgene ex-
pression. (B, C) Validation of CTS2- (B) and CTS1 (C)-mediated PCTS1/2/PCTS1/CTS2/CTS3/CTS-O3P2-driven SEAP expression in HeLa cells. HeLa cells were
cotransfected with the indicated combinations of CTS and PCTS-SEAP-encoding expression vectors at a 1:1 ratio (w/w; 0.6 g total DNA) and cultivated
for 48 h in the presence (+) or absence (−) of 0.75 mM benzoic acid before SEAP expression was scored in the culture supernatant. The data are shown
as the mean ± SD, n = 3. Fold-changes in SEAP expression of all CTS/PCTS combinations were calculated by dividing BA-induced SEAP expression
levels (0.75mM benzoic acid) by basal SEAP levels (0mM benzoic acid). (D) Reversibility of CTS1/PCTS-O3P2-driven SEAP expression. pMX34/pMX42-
cotransfected HeLa cells were cultivated for 72 h while alternating the presence (+) and absence (−) of benzoic acid (BA, 50 M) and scoring SEAP levels
in the culture supernatant every 12 h. The data are shown as the mean ± SD, n = 3. (E) Dose-dependent benzoic acid-induced SEAP expression by the
CTS1/PCTS-O3P2 device in the presence of different CTS1-inactivating vanillic acid concentrations. HeLa cells were cotransfected with pMX34 and pMX42
at a 1:1 ratio (w/w; 2 g total DNA), collected in culture medium containing different vanillic acid concentrations (0 mM, 0.75 mMor 3 mM) and reseeded
into the wells of a 96-well plate (15 000 cells in 100 l per well) containing the indicated concentrations of benzoic acid. The SEAP levels were profiled
in the culture supernatant after 48 h. The data are shown as the mean ± SD, n = 3. (F) Dose-dependent vanillic acid-repressed SEAP expression by the
CTS1/PCTS-O3P2 device in the presence of different CTS1-inducing benzoic acid concentrations. HeLa cells were cotransfected with pMX34 and pMX42 at
a 1:1 ratio (w/w; 2 g total DNA), collected in culture medium containing different benzoic acid concentrations (30 M, 150 Mor 750 M) and reseeded
into the wells of a 96-well plate (15 000 cells in 100 l per well) containing the indicated concentrations of vanillic acid. The SEAP levels were profiled in
the culture supernatant after 48 h. The data are shown as the mean ± SD, n = 3. (G, H) Control kinetics of the CTS1/PCTS-O3P2 device. HeLa cells were
cotransfected with pMX34 and pMX42 at a 1:1 ratio (w/w; 2 g total DNA) and cultivated for 96 h in the presence (+) or absence (−) of 250 Mbenzoic
acid (BA). At (G) 12 h and (H) 24 h, vanillic acid was added at different concentrations. The SEAP levels were profiled in the culture supernatant every 12
h. The data are shown as the mean ± SD, n = 3.
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Figure 3. A synthetic gene network with a vanillate control interface. (A) Componentry of the higher-order control network combining two different
orthogonal gene switches with antagonistic responses to vanillic acid, the CTS1/PCTS-O3P2 (pMX34, PhEF1-CTS1-pA; pMX42, PCTS-O3P2 -SEAP-pA)
driving SEAP expression and the VACON system (pCK189, PSV40-VanA4-pA; pMX78, PVanON8-GLuc-pA) controlling the expression of GLuc (Gaussia
princeps luciferase). The VACON system consists of a vanillic acid-dependent transsilencer VanA4, a fusion of the Caulobacter crescentus repressor VanR
and KRAB, which binds and represses PVanON8, a chimeric promoter containing an octameric VanA4-specific operator module (VanO8) 3′ of the human
cytomegalovirus immediate early promoter (PhCMV). (B) Operation of the vanillic acid-responsive designer network providing vanillic acid-triggered mu-
tually exclusive expression switches from SEAP to GLuc expression. At the same time as vanillic acid attenuates benzoate-induced CTS1/PCTS-O3P2-driven
SEAP expression, it turns on VanA4/PVanON8-driven GLuc expression. (C) Vanillic acid-programmed SEAP and GLuc expression kinetics. HeLa cells
were cotransfected with pMX34, pMX42, pCK189 and pMX78 (10:10:1:0.5 ratio [w/w]; 2g total DNA) and cultivated for 96 h in the presence or absence
of vanillic acid (VA, 1 mM) and benzoic acid (BA, 50 M). For one experimental configuration, vanillic acid (1 mM) was added after 24 h to a culture
containing benzoic acid (50 M). SEAP as well as GLuc production were profiled every 12 h. The data are shown as the mean ± SD, n = 3.
respectively (<0.1% (w/w) by FDA), no increased blood
SEAP levels could be detected (Figure 4C). Also, mice
receiving high vanillate-containing drinks such as Vanilla
Coke R© or a saturated aqueous vanillin-sugar solution (260
g/l) did not show any changes of SEAP levels in their blood-
stream (Figure 4C). Collectively, these data suggest that ac-
tivation of the CTS1/PCTS-O3P2 device in vivo is rapid (Sup-
plementary Figure S3) but remains insensitive to standard
dietary intake (Figure 4C) while responding exclusively to
higher benzoate concentrations (≤1000 mg/kg) within its
NOAEL range.
DISCUSSION
Continuous expansion of the genetic components portfo-
lio is required to design highly sophisticated devices that
programme cellular behaviour and provide novel and sus-
tainable solutions for global challenges in renewable energy
(45), food security (46) and biomedicine (28,47–49). The
availability of synthetic gene switches that allow trigger-
adjustable expression of therapeutic transgenes is particu-
larly important to provide the dynamic control behaviour
required to functionally interface with host metabolic ac-
tivities (6–9,50). To guarantee optimal interference-free op-
eration in multicellular organisms, trigger molecules that
fine-tune the expression of heterologous transgene expres-
sion are of key importance. Optimal inducer compounds
are non-toxic, enable reversible and dose-dependent trans-
gene expression and should be orally applicable for maxi-
mum administration compliance. Trigger molecules should
be bioavailable to quickly reach concentrations suitable for
efficient control in the bloodstream or elsewhere in the body
yet should be readily eliminated by renal clearance to al-
low rapid reversal of the intervention. Additionally, inducer
compounds should be metabolically inert to enable perfect
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Figure 4. Benzoate-inducible transgene expression in mice. (A) SEAP induction profiles of microencapsulated CTS1/PCTS-O3P2-transgenic HeLa cells in
vitro. In total, 2 × 106 pMX34/pMX42-transgenic microencapsulated HeLa cells (10 000 capsules, 200 cells/capsule) were cultivated per well of a 6-well
plate containing 3 ml of standard medium with or without 0.75 mM sodium benzoate. SEAP expression was profiled in the culture supernatant every 24
h. The data are shown as the mean ± SD, n = 3. (B) Antagonistic dual-input control of the CTS1/PCTS-O3P2in vivo. In total, 2 × 106 pMX34/pMX42-
transgenic microencapsulated HeLa cells (10 000 capsules, 200 cells/capsule) were intraperitoneally implanted into mice. (i) Treated mice drank 4 × 200
l H2O containing different concentrations of sodium benzoate (total daily intake: 0–1000 mg/kg). (ii) Treated mice drank 4 × 200 l sodium benzoate-
containing H2O (total daily intake: 1000 mg/kg) and received (2 × 100 l) different concentrations of vanillic acid concentrations (total daily intake:
0–500 mg/kg). The SEAP levels in the bloodstream of the treated animals were profiled after 24 h. The data are shown as the mean ± SEM, n = 8 mice.
(C) Insensitivity of the CTS1/PCTS-O3P2-device to dietary intake of standard benzoate- and vanillate-containing food. In total, 2 × 106 pMX34/pMX42-
transgenic microencapsulated HeLa cells (10 000 capsules, 200 cells/capsule) were intraperitoneally implanted into mice that drank 4 × 200 l of either
commercial soft drinks such as Guarana Antarctica, Ocean Spray cranberry juice or Vanilla CokeR©, or a custom-made vanillin syrup (260 g/l of vanillin).
Control mice either drank 4 × 200 l sodium benzoate-containing H2O (total daily intake: 1000 mg/kg) or received (2 × 100 l) of vanillic acid (total
daily intake: 500 mg/kg). The SEAP levels in the bloodstreams of the treated animals were profiled after 24 h. The data are shown as the mean ± SEM;
statistics by two-tailed t-test; n = 6 mice. ***P < 0.001 versus control.
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orthogonal control without any interference with the host
metabolism. Therefore, food additives seem to be partic-
ularly suitable trigger compounds because they are gener-
ally regarded as safe (GRAS), are licensed for dietary in-
take over a wide concentration range and have a long and
global history of complication-free use. However, the ma-
jor challenge associated with food additive-responsive gene
switches is that they should remain insensitive to standard
dietary intake and be exclusively controlled by the inten-
tional uptake of higher levels of the food additive within
its NOAEL concentration range. Benzoate meets these high
standards and therefore is an ideal trigger compound. It
is a natural plant defence metabolite present in different
fruits, such as cranberries, prunes and apples (32), and has
a long history as a licensed food preservative (51). Benzoate
is known to be metabolically inert (35), rapidly reaches
the bloodstream (34) and is renally cleared within 24 h
(34). Benzoate also is the best trigger compound that re-
versibly adjusts CbaR-derived gene switches in a variety
of configurations in mammalian cells as well as in mice.
Most importantly, implanted CbaR-derived gene switches
remained insensitive when treated animals drank Ocean
Spray cranberry juice and Guarana Antarctica lemonade,
which are among the beverages that contain the highest
natural and spiked benzoate concentrations, respectively.
This result indicates that the CbaR-derived gene switch is
not deregulated by standard dietary intake of benzoate (0–
5 mg/kg body weight (37)) and remains exclusively sensi-
tive to higher concentrations (500–1000 mg/kg) within the
NOAEL range (33,37). Therefore, the benzoate sensitivity
range of the CbaR-derived gene switch may be compatible
with future gene- and cell-based therapies.
Currently available gene switches typically accept a sin-
gle type of control input that either induces or represses
the gene switch and modulates the expression of a single or
set of target genes (1,6,14,19,21–24). Daisy-chain assembly
of compatible trigger-controlled repressor proteins to mul-
tipartite transcription factors has recently been shown to
provide multi-input devices that are able to address differ-
ent sets of promoters in a trigger-repressible manner (25).
Asymmetries in the binding affinity of the individual re-
pressor moieties of the multipartite transcription factors
to their respective promoters exhibited double-pole double-
throw (DPDT) relay switch characteristics, a unique con-
trol topology that allows the composite transcription fac-
tor to move from one synthetic promoter to the next one
in a trigger-inducible manner, thereby sequentially and ex-
clusively switching on a specific target promoter by a par-
ticular inducer compound. In contrast, the CbaR-derived
transactivators CTA and transsilencers CTS are the first
synthetic mammalian transcription factors that antagonis-
tically fine-tune a single target promoter in response to two
different trigger molecules, such as benzoic acid and vanillic
acid, in a reversible, dose-dependent and antagonistic man-
ner: Benzoate reduces and vanillate increases the CbaR-
OCbaR interaction of the CTA/PCTA-O2 and CTS/PCTS de-
vice variants. In the absence of benzoate, vanillate can be
used to boost the expression capacity of CTA- and im-
prove the tightness of CTS-mediated transgene control,
which increases the dynamic range of both gene switches
in a trigger-controlled manner. Interestingly, benzoate and
vanillate seem to have equal access to CTA and CTS, as nei-
ther compound is dominant. Therefore, neither compound
can lock the activity of the transactivator or transsilencer
in a particular state: when primed by one compound, the
device remains sensitive to the other. The relative concen-
trations of the two compounds always determine the final
expression level of the device. The antagonistic control im-
pact allows OFF-to-ON andON-to-OFF switches to be ac-
tively controlled by a specific compound. In contrast, clas-
sic single-input gene switches require degradation or active
removal to achieve reversibility. Another unique feature of
the CTS/PCTS device is that it can be functionally com-
bined with the VACON system via vanillic acid, which stops
benzoate-induced CTS/PCTS -driven transgenes and simul-
taneously turns on VACON-driven transgenes. This genetic
lap-timing stopwatch feature may be of interest for the de-
sign of lineage-control networks for stem cells which require
timely and transient expression of specific differentiation
factors on their way to the desired terminally differentiated
cell phenotype (52). As a new addition to the synthetic bi-
ology toolbox, the dual-input CTA/PCTA-O2 and CTS/PCTS
systems, which are responsive to two different food addi-
tives, hold great promise for the design of novel and themost
compact gene network topologies that may foster advances
in gene- and cell-based therapies.
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